The main objective of this trial is to assess the effect of mild and moderate hepatic impairment (Child-Pugh classification A and B) on the pharmacokinetics, safety, and tolerability of BI 690517 in comparison with a control group with normal hepatic function.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
28
BI 690517
Omega Research Orlando, LLC
Orlando, Florida, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
Time frame: Up to 4 days
Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to 4 days
Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)
Time frame: Up to 4 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.